CSAClinical-Stage Asset Intelligence
Catalyst calendar Get the data
Home / Pfizer INC (PFE) / lorlatinib
Forward catalyst · PFE

lorlatinib

Sponsor Pfizer INC · listed as PFE

READOUT Phase 3 Confidence: medium Source: clinicaltrials

lorlatinib is a drug asset sponsored by Pfizer INC, listed as PFE. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Dec 31, 2026 (day precision, medium confidence), tied to trial NCT05059522. That trial is in Phase 3 and currently active not recruiting, studying Advanced Malignancies.

Next catalyst

Event typeREADOUT
Expected date2026-12-31
As disclosedDec 31, 2026
Date precisionday
Confidencemedium
Verify at source →

Trial & sponsor

Trial (NCT)NCT05059522
PhasePHASE3
StatusACTIVE_NOT_RECRUITING
Lead sponsorPfizer
Listed asPFE
Condition(s)Advanced Malignancies; NSCLC; Ovarian Cancer; Urothelial Cancer; Solid Tumors

Other tracked assets in the same trials — NCT05059522: axitinib, talazoparib, utomilumab.

!

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This page is one record from the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.

Get the full dataset — $499 →   More PFE catalysts

Related catalysts and sponsor